Study: NCT04802759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Giredestrant
Description: 30 milligrams (mg) orally once a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Giredestrant
Description: 30 milligrams (mg) orally once a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Giredestrant
Description: 30 milligrams (mg) orally once a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Giredestrant
Description: 30 milligrams (mg) orally once a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Giredestrant
Description: 30 milligrams (mg) orally once a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Giredestrant
Description: 30 milligrams (mg) orally once a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Giredestrant
Description: 30 milligrams (mg) orally once a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Giredestrant
Description: 30 milligrams (mg) orally once a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Giredestrant
Description: 30 milligrams (mg) orally once a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Giredestrant
Description: 30 milligrams (mg) orally once a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Giredestrant
Description: 30 milligrams (mg) orally once a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Giredestrant
Description: 30 milligrams (mg) orally once a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: 150 mg orally twice a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: 150 mg orally twice a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: 150 mg orally twice a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: 400 mg orally once a day on Days 1-21 of each 28-day cycle until unacceptable toxicity or disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inavolisib
Description: 9 mg orally once a day during each 28-day cycle until unacceptable toxicity or disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: 600 mg orally once a day on Days 1-21 of each 28-day cycle until unacceptable toxicity or disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 10 mg orally once a day during each 28-day cycle until unacceptable toxicity or disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Samuraciclib
Description: 360 mg orally once a day during each 28-day cycle until unacceptable toxicity or disease progression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PH FDC SC
Description: On Day 1 of Cycle 1 (1 cycle is 21 days), pertuzumab and trastuzumab fixed-dose combination for subcutaneous use (PH FDC SC) will be administered SC as a fixed dose formulation of 1200 mg pertuzumab, 600 mg trastuzumab, and 30,000 units hyaluronidase. On Day 1 of Cycles 2 and beyond, PH FDC SC will be administered SC once every 21 days as a fixed dose of 600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units hyaluronidase.